Login
Intercept Pharmaceuticals NASDAQ: ICPT
Intercept Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases
| Name | Intercept Pharmaceuticals |
| Ticker | ICPT |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Price | 29.46 |
| 52W Low/High | 24.48 / 99.66 |
| Market cap | 972 M |
| 1Y Total Return |
-70.44%
Weak |
| 1Y Volatility |
90.85%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Intercept Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases
Details
| Ticker | ICPT |
| Name | Intercept Pharmaceuticals |
| ISIN | US45845P1084 |
| CUSIP | 45845P108 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 1/22/21
| Close Price | 29.46 |
| 52W Low/High | 24.48 / 99.66 |
| Market cap | 972 M |
| 1Y Total Return |
-70.44%
Weak |
| 1Y Volatility |
90.85%
High Risk |
| Beta | 2.58 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -106.6% |
| Cash from Op. / Cur. Liabilities | -1.32 |
| Diluted Earnings / Share | -9.80 |
| ROE | - |
| ROIC | -56.1% |
| Price / Revenue | 3.2 |
| Price / Book | -7.5 |
| Price / CF | -4.5 |
| Current Ratio | 3.4 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | - |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
301
|
234
|
164
|
107
|
12
|
3
|
|
| Gross Profit |
294
|
231
|
162
|
107
|
12
|
3
|
|
| R&D |
204
|
241
|
202
|
186
|
131
|
107
|
|
| EBITDA |
-264
|
-289
|
-297
|
-335
|
-371
|
-172
|
|
| Operating Income |
-280
|
-305
|
-308
|
-345
|
-377
|
-175
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
33
|
33
|
30
|
25
|
25
|
24
|
|
| EPS exc. Extra |
-9.80
|
-10.87
|
-12.40
|
-14.80
|
-15.57
|
-7.43
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
591
|
802
|
557
|
560
|
812
|
717
|
|
| Cash, Eq & Invt ShortTerm |
497
|
712
|
489
|
493
|
780
|
696
|
|
| Total Current Assets |
561
|
769
|
529
|
522
|
795
|
703
|
|
| Total Non-Current Assets |
30
|
33
|
28
|
39
|
18
|
14
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
722
|
671
|
461
|
449
|
397
|
39
|
|
| Total Current Liabilities |
163
|
140
|
88
|
88
|
55
|
32
|
|
| Long Term Debt |
559
|
531
|
373
|
361
|
343
|
7
|
|
| Shareholder equity |
-130
|
131
|
96
|
112
|
415
|
678
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-215
|
-229
|
-264
|
-278
|
-319
|
-129
|
|
| Depreciation |
9
|
8
|
5
|
5
|
3
|
1
|
|
| Cash from Investing |
199
|
-218
|
-60
|
289
|
-61
|
-381
|
|
| Capex |
2
|
1
|
0
|
11
|
5
|
6
|
|
| Cash from Financing |
5
|
452
|
264
|
3
|
415
|
565
|
|
| Stock Issued |
8
|
231
|
265
|
3
|
6
|
565
|
|
| Debt (LT) Issued |
0
|
223
|
0
|
0
|
448
|
0
|
|
| Free Cash Flow |
387
|
-485
|
-377
|
-49
|
-406
|
-531
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
3.4
|
5.5
|
6.0
|
6.0
|
14.6
|
21.8
|
|
| Financial Leverage D/E |
-
|
4.02
|
3.83
|
3.15
|
0.81
|
0.00
|
|
| Return on Capital Avg |
-56.1%
|
-59.0%
|
-79.4%
|
-67.7%
|
-59.1%
|
-40.1%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available